Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-11-28

Clinical Trial Update: Anecortave Acetate Risk-Reduction Trial (AART) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Anecortave Acetate for dry age-related macular degeneration was terminated, indicating the development program for this indication di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • anecortave acetate (anecortave acetate)

Snippet

Sponsor: Alcon Research | Conditions: Dry AMD | Phase 3 | Status: TERMINATED